Learn More
The evaluation of surrogate endpoints is thought to be first studied by Prentice (1989), who presented a definition of a surrogate as well as a set of criteria. Freedman et al (2001) supplemented these criteria with the so-called proportion explained after notifying some drawbacks in Prentice's approach. Buyse et al (2000) framed the evaluation exercise(More)
In recent years, a lot of attention is placed on the selection and evaluation of biomarkers in microarray experiments. Two sets of biomarkers are of importance, namely therapeutic and prognostic. The therapeutic biomarkers would give us information on the response of the genes to treatment in relation to the response of the clinical outcome to the same(More)
The number of potential surrogate markers for clinical-trial endpoints is increasing rapidly, not in the least owing to the availability of biomarkers. At the same time, considerable development has taken place regarding statistical evaluation paradigms for such markers. As a consequence, such endpoints are given more extensive consideration for practice(More)
  • 1